American Century Companies Inc. Has $19.66 Million Position in Teva Pharmaceutical Industries (TEVA)

American Century Companies Inc. increased its position in Teva Pharmaceutical Industries (NYSE:TEVA) by 3.6% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,150,416 shares of the company’s stock after purchasing an additional 40,375 shares during the period. American Century Companies Inc. owned approximately 0.11% of Teva Pharmaceutical Industries worth $19,661,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in TEVA. Two Sigma Advisers LP bought a new position in Teva Pharmaceutical Industries in the 4th quarter worth about $118,487,000. Franklin Resources Inc. boosted its stake in Teva Pharmaceutical Industries by 8.2% in the 4th quarter. Franklin Resources Inc. now owns 79,488,139 shares of the company’s stock worth $1,506,309,000 after purchasing an additional 6,009,897 shares in the last quarter. OppenheimerFunds Inc. bought a new position in Teva Pharmaceutical Industries in the 4th quarter worth about $69,418,000. Commerzbank Aktiengesellschaft FI boosted its stake in Teva Pharmaceutical Industries by 116.2% in the 4th quarter. Commerzbank Aktiengesellschaft FI now owns 2,799,192 shares of the company’s stock worth $53,045,000 after purchasing an additional 1,504,349 shares in the last quarter. Finally, Teachers Advisors LLC boosted its stake in Teva Pharmaceutical Industries by 66.5% in the 4th quarter. Teachers Advisors LLC now owns 3,221,405 shares of the company’s stock worth $61,046,000 after purchasing an additional 1,286,637 shares in the last quarter. Institutional investors own 58.18% of the company’s stock.

A number of brokerages recently issued reports on TEVA. Vetr cut shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating and set a $23.94 price target on the stock. in a research note on Monday, January 29th. BTIG Research cut shares of Teva Pharmaceutical Industries from a “buy” rating to a “neutral” rating and set a $24.00 price target on the stock. in a research note on Thursday, January 18th. They noted that the move was a valuation call. Leerink Swann upped their target price on shares of Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the company an “underperform” rating in a research note on Friday, January 26th. ValuEngine cut shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 2nd. Finally, Credit Suisse Group set a $20.00 target price on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a research note on Monday, January 22nd. Ten investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and six have issued a buy rating to the company. Teva Pharmaceutical Industries has an average rating of “Hold” and a consensus target price of $19.82.

In other news, Director Roberto Mignone bought 750,000 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, May 10th. The stock was bought at an average cost of $19.24 per share, with a total value of $14,430,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders have sold a total of 5,684 shares of company stock valued at $105,411 in the last ninety days. Insiders own 0.43% of the company’s stock.

Teva Pharmaceutical Industries opened at $21.12 on Friday, according to Marketbeat.com. Teva Pharmaceutical Industries has a 52 week low of $20.87 and a 52 week high of $21.36. The stock has a market cap of $20.64 billion, a PE ratio of 5.37, a price-to-earnings-growth ratio of 1.66 and a beta of 0.67. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 1.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Thursday, May 3rd. The company reported $0.91 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.63 by $0.28. Teva Pharmaceutical Industries had a negative net margin of 72.36% and a positive return on equity of 18.59%. The firm had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.80 billion. During the same quarter in the prior year, the firm earned $1.06 EPS. The business’s revenue for the quarter was down 10.0% compared to the same quarter last year. sell-side analysts forecast that Teva Pharmaceutical Industries will post 2.45 EPS for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply